Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Geoff McDonough, M.D., will engage in a fireside chat scheduled for Wednesday, April 9th at 12:45 p.m. ET. Investors and interested parties can access the live webcast through the investor section at investors.generationbio.com, where a replay will remain available for 30 days after the event.
Generation Bio (Nasdaq: GBIO), una compagnia biotecnologica focalizzata sulle malattie autoimmuni guidate dalle cellule T, ha annunciato la sua partecipazione alla prossima 24ª Conferenza Virtuale Annuale Healthcare di Needham.
Il Presidente e CEO dell'azienda, Geoff McDonough, M.D., parteciperà a una chiacchierata informale programmata per mercoledì 9 aprile alle 12:45 p.m. ET. Gli investitori e le parti interessate possono accedere alla diretta tramite la sezione investitori su investors.generationbio.com, dove sarà disponibile una registrazione per 30 giorni dopo l'evento.
Generation Bio (Nasdaq: GBIO), una empresa biotecnológica centrada en enfermedades autoinmunes impulsadas por células T, ha anunciado su participación en la próxima 24ª Conferencia Virtual de Atención Médica de Needham.
El Presidente y CEO de la compañía, Geoff McDonough, M.D., participará en una charla informal programada para miércoles 9 de abril a las 12:45 p.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de inversores en investors.generationbio.com, donde una repetición estará disponible durante 30 días después del evento.
Generation Bio (Nasdaq: GBIO)는 T세포 주도의 자가면역 질환에 초점을 맞춘 생명공학 회사로, 다가오는 제24회 니드햄 가상 의료 컨퍼런스에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 Geoff McDonough, M.D.는 4월 9일 수요일 오후 12시 45분 ET에 예정된 대화에 참여할 것입니다. 투자자 및 관심 있는 분들은 investors.generationbio.com의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있으며, 이벤트 후 30일 동안 재생이 가능합니다.
Generation Bio (Nasdaq: GBIO), une entreprise de biotechnologie axée sur les maladies auto-immunes à médiation T, a annoncé sa participation à la prochaine 24e Conférence Virtuelle Annuelle de Santé de Needham.
Le Président et CEO de l'entreprise, Geoff McDonough, M.D., participera à une discussion informelle prévue pour mercredi 9 avril à 12h45 ET. Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct via la section investisseurs sur investors.generationbio.com, où une rediffusion sera disponible pendant 30 jours après l'événement.
Generation Bio (Nasdaq: GBIO), ein biotechnologisches Unternehmen, das sich auf T-Zell-gesteuerte Autoimmunerkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden 24. Virtuellen Gesundheitskonferenz von Needham angekündigt.
Der Präsident und CEO des Unternehmens, Geoff McDonough, M.D., wird an einem informellen Gespräch teilnehmen, das für Mittwoch, den 9. April um 12:45 Uhr ET geplant ist. Investoren und Interessierte können über den Investorenbereich auf investors.generationbio.com auf den Live-Stream zugreifen, wo eine Aufzeichnung 30 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
When is Generation Bio (GBIO) presenting at the Needham Healthcare Conference 2025?
How can investors watch Generation Bio's (GBIO) Needham Conference presentation?
How long will Generation Bio's (GBIO) Needham Conference presentation be available for replay?
What is Generation Bio's (GBIO) current therapeutic focus?
